Abstract
Elevated levels of plasma cholesterol are known to increase the incidence of clinical manifestations of atherosclerosis in man, A favourable effect of plasma cholesterol reduction, in terms of a diminution of the clinical complications of atherosclerosis has, on the other hand, only recently been shown. The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), in fact, which will be examined with more details later, has demonstrated that a reduction (even as little as 8%) of the plasma levels of total cholesterol results in the decrease of the risk of fatal or non fatal myocardial infarctions by 19%, and that the total death rate (death for all causes) is also positively affected, even if less strikingly, by this pharmacological treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lipid Research Clinics Program: The LRC-CPPT results. I. Reduction in the incidence of Coronary Heart Disease, JAMA 251: 351 (1984).
Lipid Research Clinics Program: The LPC-CPPT results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA 251: 365 (1984).
Committee of the principal investigators, WHO Clofibrate Trial: A cooperative trial in the primary prevention of ischemic heart disease using Clofibrate, Br Heart J 40: 1069 (1978).
Coronary Drug Project Research Group: Clofibrate and Niacine in coronary heart disease, JAMA 231: 360 (1975).
Davis CE, Havlik RJ: Clinical trials of Lipid lowering drugs and coronary artery disease prevention, in : “Hyperlipidemia Diagnosis and Therapy”, Rifkind B, Levy R, eds, Grune and Stratton inc, New York, pp 79–92 (1977).
Carvalho A, Colman RW, Lees RS: Platelet function in hyperlipidemia, N Engl J Med 290: 434 (1974).
Tremoli E, Folco GC, Agradi E, Galli C: Platelet thromboxanes and serum cholesterol, Lancet i: 107 (1979).
Tremoli E, Sirtori CR, Maderna P and Paoletti R: Enhanced platelet sensitivity and arachidonic acid metabolism associated with animal and human hyperlipidemias, in :“New Trends in Nutrition, Lipid Research and Cardiovascular disease” Alan R Riss, New York, pp 151–163 (1981).
Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M and Sirtori CR: Increased platelet sensitivity and thromboxane B2 formation in type II hyperlipoproteinemic patients, Eur J Clin Invest 14: 329 (1984).
Colli S, Lombroso M, Maderna P, Tremoli E and Nicosia S: Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIA hypercholesterolemia, Biochem Pharm 32: 1989 (1983).
Zmuda A, Dembinska-Kiec A, Chytkowski A, Griglewski RJ: Experimental atherosclerosis in rabbits. Platelet aggregation, thromboxane A2 generation and antiaggregatory potency of Prostacyclin, Prostaglandins 14: 1035 (1977).
Tremoli E, Socini A, Petroni A and Galli C: Increased platelet aggregability is associated with increased prostacyclin production by vessel wall in hypercholesterolemic rabbits, Prostaglandins 24: 397 (1982).
Sirtori CR, Catapano A, Ghiselli GC, Innocenti AL and Rodriguez J: Metformin an antiatherosclerotic agent modifying very low density10. lipoproteins in rabbits, Atherosclerosis 23: 73 (1976).
Tremoli E, Ghiselli GC, Maderna P, Colli S and Sirtori CR: Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits, Atherosclerosis 41: 53 (1982).
Tremoli E, Petroni A, Socini A, Maderna P, Colli S, Paoletti R, Galli C, Ferro-Luzzi A, Strazzullo P, Mancini M, Puska P, Iacono J and Dougherty R: Dietary interventions in North Karelia, Finland and South Italy. Modification of Thromboxane B2 formation in platelets of male subjects only, Atherosclerosis 59: 101 (1986).
De Carvalho ACA, Colman RW and Lees RS: Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia, Circulation 50: 590 (1974).
Sirtori M, Montanari G, Gianfranceschi G, Malacrida MG, Battistin P, Morazzoni G, Tremoli E, Colli S, Maderna P and Sirtori CR: Clofibrate and Tiadenol treatment in hyperlipoproteinemias, Atherosclerosis 49: 149 (1983).
Vergani C and D’Angelo A: Effet de Tiadenol sur les lipides seriques et sur le function plaquettaire, La Vie Med 2: 1 (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Poli, A., Tremoli, E., Galli, C., Paoletti, R. (1987). Dietary and Pharmacological Control of Human and Experimental Hypercholesterolemia. In: Galli, C., Fedeli, E. (eds) Fat Production and Consumption. NATO ASI Series, vol 131. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9495-6_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9495-6_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9497-0
Online ISBN: 978-1-4615-9495-6
eBook Packages: Springer Book Archive